Helix BioPharma Corp. (TSX:HBP)
Canada · Delayed Price · Currency is CAD Helix BioPharma Statistics
Total Valuation
Helix BioPharma has a market cap or net worth of CAD 71.93 million. The enterprise value is 71.22 million.
| Market Cap | 71.93M |
| Enterprise Value | 71.22M |
Important Dates
The next estimated earnings date is Monday, October 27, 2025.
| Earnings Date | Oct 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Helix BioPharma has 74.16 million shares outstanding. The number of shares has increased by 23.16% in one year.
| Current Share Class | 74.16M |
| Shares Outstanding | 74.16M |
| Shares Change (YoY) | +23.16% |
| Shares Change (QoQ) | +5.93% |
| Owned by Insiders (%) | 6.71% |
| Owned by Institutions (%) | n/a |
| Float | 44.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -51.75 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.47 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -18.10 |
Financial Position
The company has a current ratio of 0.42
| Current Ratio | 0.42 |
| Quick Ratio | 0.31 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,616.83 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -562.96% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 697.91% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.36M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.65% in the last 52 weeks. The beta is -0.81, so Helix BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.81 |
| 52-Week Price Change | -15.65% |
| 50-Day Moving Average | 0.94 |
| 200-Day Moving Average | 0.91 |
| Relative Strength Index (RSI) | 66.08 |
| Average Volume (20 Days) | 3,416 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -9.70M |
| Pretax Income | -9.53M |
| Net Income | -9.53M |
| EBITDA | -9.69M |
| EBIT | -9.70M |
| Earnings Per Share (EPS) | -0.19 |
Balance Sheet
The company has 715,000 in cash and n/a in debt, giving a net cash position of 715,000 or 0.01 per share.
| Cash & Cash Equivalents | 715,000 |
| Total Debt | n/a |
| Net Cash | 715,000 |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | -1.39M |
| Book Value Per Share | -0.03 |
| Working Capital | -1.40M |
Cash Flow
In the last 12 months, operating cash flow was -3.93 million and capital expenditures -4,000, giving a free cash flow of -3.93 million.
| Operating Cash Flow | -3.93M |
| Capital Expenditures | -4,000 |
| Free Cash Flow | -3.93M |
| FCF Per Share | -0.05 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Helix BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.16% |
| Shareholder Yield | n/a |
| Earnings Yield | -13.25% |
| FCF Yield | -5.47% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 16, 2024. It was a reverse split with a ratio of 0.2.
| Last Split Date | Aug 16, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |